September is World Alzheimer’s Month, an international campaign to raise dementia awareness and challenge stigma, and the purple ribbon is the chosen color to represent awareness for Alzheimer’s disease. The impact of this campaign is growing, but the stigmatization and misinformation that surrounds dementia remains a global issue.
Every 3 seconds, someone in the world develops dementia. Currently ranked as the 6th leading cause of death in the US, Alzheimer’s disease is the most common cause of dementia. The fatal, progressive brain disorder is characterized by an irreversible decline in cognitive and behavioral abilities that will eventually render the person completely reliant on others for basic activities in daily life.
In 2018, the estimated cost of caring for people with Alzheimer’s and other dementias in the United States amounted to $277 billion. By 2050, health care costs could rise over $1 trillion. In response, the federal government has designated fighting Alzheimer’s disease as a priority. Signed into law in 2011, the National Alzheimer’s Project Act (NAPA) ambitiously established the goal to “prevent and effectively treat Alzheimer’s disease by 2025”.
In support of Alzheimer’s disease research, Boster Bio has built a comprehensive portfolio of ELISA kits & antibodies related to Alzheimer’s disease . In addition, visit Alzheimers.gov to find out more about the disease, stay up-to-date with research news, and learn more about research funding.